Supplementary Table S4 from The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide
Publication
, Other
Halabi, S; Guo, S; Park, JJ; Nanus, DM; George, DJ; Antonarakis, ES; Danila, DC; Szmulewitz, RZ; McDonnell, DP; Norris, JD; Lu, C; Luo, J ...
March 15, 2024
Duke Scholars
Citation
APA
Chicago
ICMJE
MLA
NLM
Halabi, S., Guo, S., Park, J. J., Nanus, D. M., George, D. J., Antonarakis, E. S., … Armstrong, A. J. (2024). Supplementary Table S4 from The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide. https://doi.org/10.1158/1078-0432.25415364.v1
Halabi, Susan, Siyuan Guo, Joseph J. Park, David M. Nanus, Daniel J. George, Emmanuel S. Antonarakis, Daniel Costin Danila, et al. “Supplementary Table S4 from The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide,” March 15, 2024. https://doi.org/10.1158/1078-0432.25415364.v1.
Halabi S, Guo S, Park JJ, Nanus DM, George DJ, Antonarakis ES, et al. Supplementary Table S4 from The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide. 2024.
Halabi, Susan, et al. Supplementary Table S4 from The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide. 15 Mar. 2024. Crossref, doi:10.1158/1078-0432.25415364.v1.
Halabi S, Guo S, Park JJ, Nanus DM, George DJ, Antonarakis ES, Danila DC, Szmulewitz RZ, McDonnell DP, Norris JD, Lu C, Luo J, Armstrong AJ. Supplementary Table S4 from The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide. 2024.